114 related articles for article (PubMed ID: 8653684)
21. p16 (CDKN2/cyclin-dependent kinase-4 inhibitor/multiple tumor suppressor-1) gene is not altered in uterine cervical carcinomas or cell lines.
Hirama T; Miller CW; Wilczynski SP; Koeffler HP
Mod Pathol; 1996 Jan; 9(1):26-31. PubMed ID: 8821952
[TBL] [Abstract][Full Text] [Related]
22. Genetic alterations of p16INK4a and p53 genes in sporadic dysplastic nevus.
Lee JY; Dong SM; Shin MS; Kim SY; Lee SH; Kang SJ; Lee JD; Kim CS; Kim SH; Yoo NJ
Biochem Biophys Res Commun; 1997 Aug; 237(3):667-72. PubMed ID: 9299424
[TBL] [Abstract][Full Text] [Related]
23. Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
Fujishita T; Mizushima Y; Kashii T; Kobayashi M
Anticancer Res; 1998; 18(3A):1537-42. PubMed ID: 9673367
[TBL] [Abstract][Full Text] [Related]
24. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia.
Ruiz A; Puig S; Malvehy J; Lázaro C; Lynch M; Gimenez-Arnau AM; Puig L; Sánchez-Conejo J; Estivill X; Castel T
J Med Genet; 1999 Jun; 36(6):490-3. PubMed ID: 10874641
[TBL] [Abstract][Full Text] [Related]
25. Deletion map of chromosome 9 and p16 (CDKN2A) gene alterations in neuroblastoma.
Takita J; Hayashi Y; Kohno T; Yamaguchi N; Hanada R; Yamamoto K; Yokota J
Cancer Res; 1997 Mar; 57(5):907-12. PubMed ID: 9041193
[TBL] [Abstract][Full Text] [Related]
26. CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF.
Rutter JL; Goldstein AM; Dávila MR; Tucker MA; Struewing JP
Oncogene; 2003 Jul; 22(28):4444-8. PubMed ID: 12853981
[TBL] [Abstract][Full Text] [Related]
27. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family.
Knappskog S; Geisler J; Arnesen T; Lillehaug JR; Lønning PE
Genes Chromosomes Cancer; 2006 Dec; 45(12):1155-63. PubMed ID: 17001621
[TBL] [Abstract][Full Text] [Related]
28. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families.
Mantelli M; Barile M; Ciotti P; Ghiorzo P; Lantieri F; Pastorino L; Catricalà C; Torre GD; Folco U; Grammatico P; Padovani L; Pasini B; Rovini D; Queirolo P; Rainero ML; Santi PL; Sertoli RM; Goldstein AM; Bianchi-Scarrà G; ;
Am J Med Genet; 2002 Jan; 107(3):214-21. PubMed ID: 11807902
[TBL] [Abstract][Full Text] [Related]
29. Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population.
Biden K; Young J; Buttenshaw R; Searle J; Cooksley G; Xu DB; Leggett B
Hepatology; 1997 Mar; 25(3):593-7. PubMed ID: 9049204
[TBL] [Abstract][Full Text] [Related]
30. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development.
Pollock PM; Welch J; Hayward NK
Cancer Res; 2001 Feb; 61(3):1154-61. PubMed ID: 11221846
[TBL] [Abstract][Full Text] [Related]
31. Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma.
Liu L; Dilworth D; Gao L; Monzon J; Summers A; Lassam N; Hogg D
Nat Genet; 1999 Jan; 21(1):128-32. PubMed ID: 9916806
[TBL] [Abstract][Full Text] [Related]
32. A melanoma-associated germline mutation in exon 1beta inactivates p14ARF.
Rizos H; Puig S; Badenas C; Malvehy J; Darmanian AP; Jiménez L; Milà M; Kefford RF
Oncogene; 2001 Sep; 20(39):5543-7. PubMed ID: 11571653
[TBL] [Abstract][Full Text] [Related]
33. [Tribulations of the p16/MTS1/CDKN2 tumor gene suppressor: a continuing saga].
Larsen CJ
Bull Cancer; 1997 Apr; 84(4):427-30. PubMed ID: 9238169
[TBL] [Abstract][Full Text] [Related]
34. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
Piccinin S; Doglioni C; Maestro R; Vukosavljevic T; Gasparotto D; D'Orazi C; Boiocchi M
Int J Cancer; 1997 Feb; 74(1):26-30. PubMed ID: 9036865
[TBL] [Abstract][Full Text] [Related]
35. Mutation of the p16/CDKN2 gene and loss of heterozygosity in malignant mucosal melanoma and adenoid cystic carcinoma of the head and neck.
Suzuki N; Onda T; Yamamoto N; Katakura A; Mizoe JE; Shibahara T
Int J Oncol; 2007 Nov; 31(5):1061-7. PubMed ID: 17912431
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in the molecular genetics of malignant melanoma.
Haluska FG; Housman DE
Cancer Surv; 1995; 25():277-92. PubMed ID: 8718523
[TBL] [Abstract][Full Text] [Related]
37. Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds.
Walker GJ; Hussussian CJ; Flores JF; Glendening JM; Haluska FG; Dracopoli NC; Hayward NK; Fountain JW
Hum Mol Genet; 1995 Oct; 4(10):1845-52. PubMed ID: 8595405
[TBL] [Abstract][Full Text] [Related]
38. A locus linked to p16 modifies melanoma risk in Dutch familial atypical multiple mole melanoma (FAMMM) syndrome families.
van der Velden PA; Sandkuijl LA; Bergman W; Hille ET; Frants RR; Gruis NA
Genome Res; 1999 Jun; 9(6):575-80. PubMed ID: 10400925
[TBL] [Abstract][Full Text] [Related]
39. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.
Borg A; Sandberg T; Nilsson K; Johannsson O; Klinker M; Måsbäck A; Westerdahl J; Olsson H; Ingvar C
J Natl Cancer Inst; 2000 Aug; 92(15):1260-6. PubMed ID: 10922411
[TBL] [Abstract][Full Text] [Related]
40. Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B.
Soto JL; Cabrera CM; Serrano S; López-Nevot MA
BMC Cancer; 2005 Apr; 5():36. PubMed ID: 15819981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
